Akebia Therapeutics reported a decrease in total revenues to $42.0 million for the third quarter of 2023, compared to $48.7 million for the third quarter of 2022. Net loss was $14.5 million, significantly lower than the $54.1 million net loss in the same quarter of the previous year. The company's cash position remains strong, with $48.2 million in cash, cash equivalents, and restricted cash as of September 30, 2023.